title: Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Pazo Cid
authors.forename: Juan
authors.initials: J
authors.lastname: Lao
authors.forename: Manuela
authors.initials: M
authors.lastname: Lanzuela
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use*; D023381:Endpoint Determination; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D004317:Doxorubicin; D000077157:Sorafenib